D-Phe-Pro-Arg-H sulfate (GYKI-14166) is a highly active and selective inhibitor of thrombin both in vitro and in vivo. Recent studies on the stability of D-Phe-Pro-Arg-H in neutral aqueous solution at higher temperature have revealed that it is transformed into inactive 5,6,8,9,10,10a-hexahydro-2-(3'- guanidinopropyl)-5-benzyl-6-oxo- imidazo[1,2-a]pyrrolo[2,1-c]pyrazine. No such inactivation could be observed with Boc-D-Phe-Pro-Arg-H (GYKI-14451), but this compound was far less specific than the free peptide as it inhibited thrombin and, for instance, plasmin equally well. Assuming that the transformation of free tripeptide aldehyde, mentioned above, can only be initiated by a primary amino terminus, the N-alkyl derivatives of D-Phe-Pro-Arg-H were prepared. Of the new analogues, D-MePhe-Pro-Arg-H (GYKI-14766) proved to be as highly active and selective anticoagulant as its parent compound and was not inactivated by transformation into a heterocyclic compound.
Three novel enantiomerically pure chiral pyridino-18-crown-6 ligands [(S,S)-7, (S,S)-8 and (R,R)-9] containing a linker with a terminal carboxyl function were prepared. One of them [(R,R)-9] containing two tert-butyl groups at the stereogenic centers was covalently attached to silica gel by an amide bond using 3-aminopropyltrimethoxysilane. The resulting chiral stationary phase [(R,R)-11] separated the enantiomers of racemic R-(1-naphthyl)ethylammonium perchlorate and 1-phenylethylammonium perchlorate by high-performance liquid chromatography.
The discriminating efficiency of pyridino- (1), pyridono- and thiopyridono- (2), phenazino- (3), and acridino- (4) 18-crown-6 hosts as well as pyridino- (1) and phenazino- (3) 18-crown-6 hosts with allylic moieties attached either to the macrocyclic ring [X=CH-CH(2)-CH=CH(2) or C(CH(2)-CH=CH(2))(2)] or to the heterocyclic subunit was probed by circular dichroism (CD) spectroscopy using enantiomers of alpha-(1-naphthyl)- ethylamine hydrogen perchlorate (1-NEA). The CD spectra of the diastereomeric complexes as well as the difference and sum of the spectra were analyzed. Titration experiments were also performed monitored by CD or UV spectroscopy. The CD- and (1)H NMR-based enantiomeric preferences were compared. CD spectroscopy showed that the relative stability of heterochiral [(R,R)-host/(S)-guest or (S,S)-host/(R)-guest] complexes generally exceeds that of homochiral [(R,R)/(R)-or (S,S)/(S)] complexes. Bulkier substituents (R=iBu, sBu or tBu) decrease complex stability but increase the discriminating power of the host. According to (1)H NMR titration, attachment of one allylic linker group in position X of the macro ring [(S,S)-1b, (S,S)-1e] changes the discriminating preference (from heterochiral to homochiral) of the parent hosts (S,S)-1a and (S,S)-1d. This change of discriminating preference was not reflected in the CD spectra. Host (S,S)-1g with an allyloxy linker group in position gamma of the pyridine ring gives CD spectra which clearly reflect the high discriminating power and enantiomeric preference of the host. The exciton-coupled circular dichroism (ECCD) spectra of the 1-NEA complexes of phenazino and acridino hosts allow reliable determination of the enantiomeric preference by comparing the A values of the exciton couplets. An allylic group appended to the macrocyclic ring or the N-containing heterocyclic subunit allows for the attachment of the chiral discriminator to the solid matrix of a chromatographic sorbent and also serves as a spectroscopic label of the host. CD spectroscopy is a simple and rapid method, providing qualitative information on enantiomeric discrimination. It can be of great help in designing and testing new host molecules.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.